Table of Contents
PISCATAWAY, N.J. –.Camber Pharmaceuticals announces the addition of capecitabine tablets, USP, to our product portfolio. Capecitabine is a nucleoside metabolic inhibitor indicated for the treatment of several cancers, including:
• Colorectal Cancer
• Breast Cancer
• Gastric, Esophageal, or Gastroesophageal Junction Cancer
• Pancreatic Cancer
For more information about these indications, please visit our website: www.camberpharma.com/capecitabine. Capecitabine tablets, USP are available in the following strengths and packaging options:
150 mg – 60 count bottles
500 mg – 60 count and 120 count bottles
